A. Repa

发表

Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity

C. Howald, E. Dermitzakis, H. Ongen, 2019, Annals of the rheumatic diseases.

THU0367 Familial Mediterranean Fever (FMF): A Single Center Clinical-Genetic Study

G. Goulielmos, D. Boumpas, G. Bertsias, 2014 .

Comparative analysis of the sensitivity and specificity of the classification criteria and correlation with prognosis of disease in patients with Systemic Lupus Erythematosus

G. Bertsias, A. Fanouriakis, P. Sidiropoulos, 2018, Mediterranean journal of rheumatology.

Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence.

D. Vassilopoulos, A. Fanouriakis, P. Sidiropoulos, 2015, Seminars in arthritis and rheumatism.

Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up.

G. Bertsias, A. Fanouriakis, P. Sidiropoulos, 2018, Rheumatology.

Delays in assessment of patients with rheumatoid arthritis: variations across Europe

C. Turesson, S. Rantapää-Dahlqvist, H. Mann, 2011, Annals of the rheumatic diseases.

Dysregulated production of interleukin-1β upon activation of the NLRP3 inflammasome in patients with familial Mediterranean fever.

G. Goulielmos, D. Boumpas, G. Bertsias, 2015, Human immunology.

Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study

P. Sidiropoulos, A. Repa, N. Kougkas, 2022, Arthritis Research & Therapy.

Persistence of Depression and Anxiety despite Short-Term Disease Activity Improvement in Patients with Systemic Lupus Erythematosus: A Single-Centre, Prospective Study

C. Lionis, G. Bertsias, P. Sidiropoulos, 2022, Journal of clinical medicine.

Patterns and factors associated with pneumococcal vaccination in a prospective cohort of 1,697 patients with rheumatoid arthritis

G. Kitas, P. Sfikakis, P. Voulgari, 2023, Frontiers in Medicine.

The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study

D. Psaltis, D. Vassilopoulos, L. Settas, 2022, Rheumatology International.

Nailfold Videocapillaroscopy as a Candidate Biomarker for Organ Involvement and Prognosis in Patients with Systemic Sclerosis

G. Bertsias, P. Sidiropoulos, A. Repa, 2019, Mediterranean journal of rheumatology.

Differential Expression of miR‐4520a Associated With Pyrin Mutations in Familial Mediterranean Fever (FMF)

Hyun-Dong Chang, D. Kardassis, J. Grün, 2016, Journal of cellular physiology.

Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study.

G. Sourvinos, G. Bertsias, A. Fanouriakis, 2018, Clinical and experimental rheumatology.

Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus

D. Nikolopoulos, D. Boumpas, A. Bortoluzzi, 2021, Annals of the Rheumatic Diseases.

Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece

L. Chatzi, D. Boumpas, G. Bertsias, 2017, Annals of the rheumatic diseases.

Familial Mediterranean Fever in Crete: a genetic and structural biological approach in a population of ‘intermediate risk’

E. Eliopoulos, E. Galanakis, P. Sidiropoulos, 2007, Clinical genetics.

Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis

D. Boumpas, G. Bertsias, K. Kambas, 2015, Arthritis Research & Therapy.

Genomic dissection of Systemic Lupus Erythematosus: Distinct Susceptibility, Activity and Severity Signatures

C. Howald, E. Dermitzakis, H. Ongen, 2018, bioRxiv.

Screening for cognitive impairment in systemic lupus erythematosus: Application of the Montreal Cognitive Assessment (MoCA) in a Greek patient sample

E. Karademas, Georgia Dimitraki, G. Bertsias, 2021, Lupus.

Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study

A. Elezoglou, D. Nikolopoulos, D. Boumpas, 2023, Frontiers in Immunology.

Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus

D. Boumpas, K. Boki, G. Bertsias, 2020, Mediterranean journal of rheumatology.

Patient and partner dispositional optimism as a long-term predictor of illness representations in autoimmune diseases

P. Simos, E. Karademas, Georgia Dimitraki, 2017, Journal of health psychology.

Adaptation to inflammatory rheumatic disease: Do illness representations predict patients’ physical functioning over time? A complex relationship

P. Simos, E. Karademas, Georgia Dimitraki, 2018, Journal of Behavioral Medicine.

Emotion regulation contributes to the well-being of patients with autoimmune diseases through illness-related emotions: A prospective study

P. Simos, E. Karademas, Georgia Dimitraki, 2018, Journal of health psychology.

Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis.

G. Kitas, P. Sfikakis, P. Voulgari, 2020, Rheumatology.

Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection.

D. Vassilopoulos, D. Boumpas, A. Fanouriakis, 2014, Rheumatology.

AB1041 BIOLOGICS IN ADULT’S ONSET STILL’S DISEASE: TREATMENT STRATEGIES AND SAFETY IN SINGLE CENTER COHORT WITH LONG-TERM FOLLOW-UP

G. Bertsias, A. Repa, N. Kougkas, 2020, Annals of the Rheumatic Diseases.

Control of flares and relief of urate burden with canakinumab and targeted urate-lowering therapy in tophaceous gouty arthritis.

A. Karantanas, A. Fanouriakis, P. Sidiropoulos, 2014, Rheumatology.

The relation of partners’ illness representations to the coping behaviors of patients with inflammatory rheumatic diseases through patients’ illness representation: A dyadic regulation process

P. Simos, A. Vgontzas, E. Karademas, 2022, Current Psychology.

Correction: Nikoloudaki et al. Persistence of Depression and Anxiety despite Short-Term Disease Activity Improvement in Patients with Systemic Lupus Erythematosus: A Single-Centre, Prospective Study. J. Clin. Med. 2022, 11, 4316

C. Lionis, G. Bertsias, P. Sidiropoulos, 2022, Journal of clinical medicine.

Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.

G. Bertsias, P. Sidiropoulos, A. Repa, 2023, Rheumatology international.

FRI0244 Low dose of rituximab is effective for maintenance of clinical remission or low disease activity in patients with rheumatoid arthritis

B. Hsu, G. Bertsias, A. Fanouriakis, 2017 .

Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with ‘difficult to treat’ rheumatoid arthritis

G. Bertsias, P. Sidiropoulos, A. Repa, 2024, RMD Open.

Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression

A. Bortoluzzi, G. Bertsias, A. Fanouriakis, 2024, Annals of the Rheumatic Diseases.